Absci
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
18105 SE Mill Plain Blvd, Vancouver, Was...Phone Number
(360) 949-1041Website
www.absci.comRevenue
<$5 MillionStock Symbol
ABSIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Absci
Absci Corporation is a biotechnology company that combines artificial intelligence, data science, and advanced biological research to transform the discovery and development of innovative therapeutic medicines. The company specializes in the creation of biologic drug candidates by integrating generative artificial intelligence with laboratory experimentation, enabling a more efficient and data-driven approach to drug discovery.Explore more
Absci Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Absci your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Absci recently announced quarterly report
Product Launch: Get notified when Absci launches new products
Click to see if Absci had a recent Job posting/layoffs
Check if Absci has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Absci has new funding data
Absci, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Absci is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Absci
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Absci
Compare insights from companies similar to Absci, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Absci is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Absci is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Absci.
Absci financials insights
Gather financial insights about Absci, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$5.1M
2018
Series C
$12M
2020
Multiple Rounds
$80.8M
2021
Other Financing Round
$125M
2025
Other Financing Round
$64M
Absci Tech Stack
A closer look at the technologies used by Absci
Most Recent Scoops
Person-Based
Proof of Concept (POC)
Person-Based
Earnings, Clinical Operations, Finance
Project
Absci has announced plans to initiate a Phase II study for endometriosis in Q4 of this year, based on safety, tolerability, and pharmacokinetic data generated in the single ascending dose portion of the HEADLINE trial.
Pharmaceuticals, Clinical Operations
Project
Absci has announced that the multiple ascending dose portion of the HEADLINE trial continues to enroll according to plan, with an interim proof of concept readout in the form of 13-week data anticipated later this year and full proof of concept data in the form of 26-week data expected in early 2027.
Proof of Concept (POC)
Person-Based
Board of Directors, Pharmaceuticals
Absci News & Media
Absci Q2 Earnings Call Highlights
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from ElAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
Issued on behalf of MindWalk Holdings Corp. MindWalk Holdings Corp. (NASDAQ: HYFT) filed a European patent application directed to the high-dimensional biological data architecture beneath its HYFT® Technology, ReefIQ™, and LensAI™, the model-agnostic context layer designed to let AI...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Absci
Sign Up For FreeTo access detailed company insights
Absci Corporation is a biotechnology company that combines artificial intelligence, data science, and advanced biological research to transform the discovery and development of innovative therapeutic medicines. The company specializes in the creation of biologic drug candidates by integrating generative artificial intelligence with laboratory exper... Read More
